Dose response of two synthetic human growth hormone-releasing factors on growth hormone release in heifers and pigs.
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10). In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square design. In each square, there were five animals injected with either hGRF (1-44)NH2 or hGRF (1-29)NH2. Main effects were doses (n = 5) of hGRF and days (n = 5) of injection. In both species, data indicated that hGRF (1-44)NH2 and hGRF (1-29)NH2 equally stimulate GH secretion at all doses. In dairy heifers, average peak concentrations (81.7, 94.7, 84.5 and 93.7 ng.ml-1 vs 91.5, 81.0, 94.3 and 91.6 ng.ml-1) and area under the GH response curve (3,661, 4,541, 7,196 and 6,788 ng.ml-1.min vs 3,000, 3,982, 5,639 and 6,724 ng.ml-1.min) were not different (P greater than .05) between hGRF(1-44)NH2 and hGRF(1-29)NH2 at .067, .2, .6 and 1.8 nmol.kg-1, respectively. Similarly, in pigs, average peak concentrations (35.6, 38.6, 76.5 and 73.8 ng.ml-1 vs 28.7, 30.0, 41.3 and 80.8 ng.ml-1) and area under the GH curve (1,576, 1,567, 3,299 and 3,622 ng.ml-1.min vs 1,115, 1,658, 1,482 and 2,528 ng.ml-1.min) were not different (P greater than .05) between both peptides. A biphasic release of GH after hGRF (1-44)NH2 and hGRH (1-29)NH2 injection was observed at the highest dose in heifers. The GH response to hGRF injection was much more variable in pigs as compared with dairy heifers. In conclusion, hGRF (1-44)NH2 and its (1-29)NH2 fragment are equipotent in stimulating GH release in dairy heifers and pigs.
D000818:Animals; D002417:Cattle / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D007275:Injections, Intravenous; D010187:Pancreatic Hormones / Q000008:administration & dosage / Q000494:pharmacology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D017337:Sermorelin; D013552:Swine / Q000502:physiology*
D010187:Pancreatic Hormones; D010446:Peptide Fragments; C040786:somatotropin releasing hormone (1-44)amide; D017337:Sermorelin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone